Table 3. Incidence of Adverse Events (Frequency in ≥5.0% of Participants) in Subjects Treated with Vortioxetine, Duloxetine, or Placebo for 8 Weeks.

	Placebo, n=191	Vortioxetine, n=196	Duloxetine, n=207
Treatment-emergent adverse events (TEAEs), subjects, n (%)
Any TEAE	85 (44.5%)	117 (59.7%)	119 (57.5%)
TEAEs leading to discontinuation	7 (3.7%)	7 (3.6%)	13 (6.3%)
Serious TEAEs	2 (1.0%)	1 (0.5%)	1 (0.5%)
Serious TEAEs leading to discontinuation	1 (0.5%)	0	1 (0.5%)
TEAEs with incidence of ≥5% in any treatment arm, subjects, n (%)
Nausea	8 (4.2%)	40 (20.4%)	43 (20.8%)
Headache	16 (8.4%)	20 (10.2%)	24 (11.6%)
Diarrhea	5 (2.6%)	11 (5.6%)	6 (2.9%)
Nasopharyngitis	11 (5.8%)	7 (3.6%)	8 (3.9%)
Dizziness	5 (2.6%)	6 (3.1%)	11 (5.3%)
Dry mouth	9 (4.7%)	6 (3.1%)	16 (7.7%)
Decreased appetite	1 (0.5%)	3 (1.5%)	12 (5.8%)